Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation. more
Time Frame | ABVC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.69% | -3.39% | -3.47% |
1-Month Return | -4.98% | -3.25% | -0.29% |
3-Month Return | -26.52% | -11.61% | 4.5% |
6-Month Return | -32.87% | -5.89% | 6.91% |
1-Year Return | -58.9% | 2.65% | 23.79% |
3-Year Return | -98.65% | 0.56% | 28.43% |
5-Year Return | -99.11% | 34.63% | 83.64% |
10-Year Return | -99.98% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 701.72K | 483.05K | 355.80K | 969.78K | 152.43K | [{"date":"2019-12-31","value":72.36,"profit":true},{"date":"2020-12-31","value":49.81,"profit":true},{"date":"2021-12-31","value":36.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":15.72,"profit":true}] |
Cost of Revenue | 20.14K | 18.72K | 5.09K | 286.42K | 302.04K | [{"date":"2019-12-31","value":6.67,"profit":true},{"date":"2020-12-31","value":6.2,"profit":true},{"date":"2021-12-31","value":1.68,"profit":true},{"date":"2022-12-31","value":94.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 681.58K | 464.33K | 350.71K | 683.37K | (149.61K) | [{"date":"2019-12-31","value":99.74,"profit":true},{"date":"2020-12-31","value":67.95,"profit":true},{"date":"2021-12-31","value":51.32,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-21.89,"profit":false}] |
Gross Margin | 97.13% | 96.13% | 98.57% | 70.47% | (98.15%) | [{"date":"2019-12-31","value":98.54,"profit":true},{"date":"2020-12-31","value":97.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":71.49,"profit":true},{"date":"2023-12-31","value":-99.57,"profit":false}] |
Operating Expenses | 4.14M | 8.97M | 11.70M | 15.80M | 8.07M | [{"date":"2019-12-31","value":26.21,"profit":true},{"date":"2020-12-31","value":56.78,"profit":true},{"date":"2021-12-31","value":74.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":51.06,"profit":true}] |
Operating Income | (3.46M) | (8.51M) | (11.35M) | (15.11M) | (8.22M) | [{"date":"2019-12-31","value":-345877800,"profit":false},{"date":"2020-12-31","value":-850577600,"profit":false},{"date":"2021-12-31","value":-1134507000,"profit":false},{"date":"2022-12-31","value":-1511441200,"profit":false},{"date":"2023-12-31","value":-821650900,"profit":false}] |
Total Non-Operating Income/Expense | (1.01M) | (2.64M) | 311.13K | (506.33K) | (4.75M) | [{"date":"2019-12-31","value":-324.68,"profit":false},{"date":"2020-12-31","value":-849.22,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-162.74,"profit":false},{"date":"2023-12-31","value":-1525.3,"profit":false}] |
Pre-Tax Income | (4.01M) | (10.81M) | (11.21M) | (15.51M) | (10.65M) | [{"date":"2019-12-31","value":-401028100,"profit":false},{"date":"2020-12-31","value":-1081393600,"profit":false},{"date":"2021-12-31","value":-1121082700,"profit":false},{"date":"2022-12-31","value":-1551459600,"profit":false},{"date":"2023-12-31","value":-1065428200,"profit":false}] |
Income Taxes | (77.04K) | (220.35K) | 825.02K | 797.78K | 256.01K | [{"date":"2019-12-31","value":-9.34,"profit":false},{"date":"2020-12-31","value":-26.71,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.7,"profit":true},{"date":"2023-12-31","value":31.03,"profit":true}] |
Income After Taxes | (3.93M) | (10.59M) | (12.04M) | (16.31M) | (10.91M) | [{"date":"2019-12-31","value":-393324000,"profit":false},{"date":"2020-12-31","value":-1059358400,"profit":false},{"date":"2021-12-31","value":-1203585100,"profit":false},{"date":"2022-12-31","value":-1631237400,"profit":false},{"date":"2023-12-31","value":-1091028800,"profit":false}] |
Income From Continuous Operations | (3.93M) | (10.59M) | (12.04M) | (16.31M) | (10.91M) | [{"date":"2019-12-31","value":-393324000,"profit":false},{"date":"2020-12-31","value":-1059358400,"profit":false},{"date":"2021-12-31","value":-1203585100,"profit":false},{"date":"2022-12-31","value":-1631237400,"profit":false},{"date":"2023-12-31","value":-1091028800,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.93M) | (10.59M) | (12.04M) | (16.31M) | (10.52M) | [{"date":"2019-12-31","value":-393324000,"profit":false},{"date":"2020-12-31","value":-1059358400,"profit":false},{"date":"2021-12-31","value":-1203585100,"profit":false},{"date":"2022-12-31","value":-1631237400,"profit":false},{"date":"2023-12-31","value":-1051565600,"profit":false}] |
EPS (Diluted) | (0.22) | (0.51) | (0.51) | (0.52) | (1.95) | [{"date":"2019-12-31","value":-21.6,"profit":false},{"date":"2020-12-31","value":-51.49,"profit":false},{"date":"2021-12-31","value":-51,"profit":false},{"date":"2022-12-31","value":-52,"profit":false},{"date":"2023-12-31","value":-195.4,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ABVC | |
---|---|
Cash Ratio | 0.03 |
Current Ratio | 0.34 |
Quick Ratio | 0.36 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ABVC | |
---|---|
ROA (LTM) | -44.55% |
ROE (LTM) | -320.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ABVC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.45 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ABVC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 43.54 |
P/B | 0.71 |
Price/FCF | 35 |
EV/R | 15.72 |
EV/Ebitda | NM |
ABVC Biopharma Inc (ABVC) share price today is $0.521
Yes, Indians can buy shares of ABVC Biopharma Inc (ABVC) on Vested. To buy ABVC Biopharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABVC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of ABVC Biopharma Inc (ABVC) via the Vested app. You can start investing in ABVC Biopharma Inc (ABVC) with a minimum investment of $1.
You can invest in shares of ABVC Biopharma Inc (ABVC) via Vested in three simple steps:
The 52-week high price of ABVC Biopharma Inc (ABVC) is $2.45. The 52-week low price of ABVC Biopharma Inc (ABVC) is $0.41.
The price-to-earnings (P/E) ratio of ABVC Biopharma Inc (ABVC) is
The price-to-book (P/B) ratio of ABVC Biopharma Inc (ABVC) is 0.71
The dividend yield of ABVC Biopharma Inc (ABVC) is 0.00%
The market capitalization of ABVC Biopharma Inc (ABVC) is $5.94M
The stock symbol (or ticker) of ABVC Biopharma Inc is ABVC